NO975709L - Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter - Google Patents

Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter

Info

Publication number
NO975709L
NO975709L NO975709A NO975709A NO975709L NO 975709 L NO975709 L NO 975709L NO 975709 A NO975709 A NO 975709A NO 975709 A NO975709 A NO 975709A NO 975709 L NO975709 L NO 975709L
Authority
NO
Norway
Prior art keywords
steroids
vomeroferin
new
steroid
hypothalamic effects
Prior art date
Application number
NO975709A
Other languages
English (en)
Norwegian (no)
Other versions
NO975709D0 (no
Inventor
Clive L Jennings-White
David L Berliner
Nathan William Adams
Original Assignee
Pherin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Pharm Inc filed Critical Pherin Pharm Inc
Publication of NO975709D0 publication Critical patent/NO975709D0/no
Publication of NO975709L publication Critical patent/NO975709L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO975709A 1995-06-07 1997-12-05 Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter NO975709L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/485,615 US5792757A (en) 1994-08-04 1995-06-07 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
PCT/US1996/009665 WO1996040727A1 (en) 1995-06-07 1996-06-07 Novel nor-pregnanes for inducing hypothalamic effects

Publications (2)

Publication Number Publication Date
NO975709D0 NO975709D0 (no) 1997-12-05
NO975709L true NO975709L (no) 1998-02-05

Family

ID=23928825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975709A NO975709L (no) 1995-06-07 1997-12-05 Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter

Country Status (17)

Country Link
US (3) US5792757A (de)
EP (1) EP0830369B1 (de)
JP (1) JPH11507360A (de)
KR (1) KR19990022640A (de)
CN (1) CN1191542A (de)
AT (1) ATE240344T1 (de)
AU (1) AU724787B2 (de)
BR (1) BR9609012A (de)
CA (1) CA2223397C (de)
CZ (1) CZ391597A3 (de)
DE (1) DE69628163T2 (de)
EA (1) EA000965B1 (de)
ES (1) ES2197949T3 (de)
HU (1) HUP9900887A3 (de)
NO (1) NO975709L (de)
NZ (1) NZ312303A (de)
WO (1) WO1996040727A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US6066627A (en) * 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US6331534B1 (en) 1994-08-04 2001-12-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate pain
US6117860A (en) * 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US5922699A (en) * 1996-06-07 1999-07-13 Pherin Corporation 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
ATE342721T1 (de) * 1996-07-23 2006-11-15 Pherin Pharm Inc Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US6555531B1 (en) * 1999-12-30 2003-04-29 Pherin Pharmaceuticals, Inc. Weight promoting composition, method, and product
US6413951B2 (en) * 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
WO2009039103A2 (en) * 2007-09-17 2009-03-26 Human Pheromone Sciences, Inc. Fragrance compositions and other compositions which contain naturally occurring substances found in corals
EP2278880B1 (de) 2008-04-09 2012-10-10 Pherin Pharmaceuticals, Inc. Steroidbehandlung für hitzewallungen
EP2398500B1 (de) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Arzneiabgabesystem auf glutathion-basis
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
CN113527400B (zh) * 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
EP3194417B1 (de) * 2014-09-17 2020-10-28 Prevacus, Inc. Ent-19-norprogesteron zur behandlung von hirntrauma
DE102020204507A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Weichspüler mit aphrodisierend wirkenden Duftstoffen
DE102020204509A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Waschmittel mit Pheromonen
DE102020204506A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Weichspüler mit Pheromonen
DE102020204505A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Wasch-/Pflegeartikel umfassend Pheromone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL287863A (de)
US2840582A (en) * 1953-08-31 1958-06-24 Searle & Co Derivatives of 13-methyl-17-hydroxy-1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17-tetradecahydro-15h-cyclopenta[a]phenanthren-3-ones
DE1297603B (de) 1964-08-08 1969-06-19 Schering Ag Verfahren zur Herstellung von 3-Keto-delta 17(20)-pregnenen
ES319318A1 (es) 1964-11-13 1966-10-16 American Cyanamid Co Procedimiento para la preparaciën de una composiciën anticonceptiva
US3385849A (en) * 1965-07-01 1968-05-28 Hoffmann La Roche Process for the preparation of 17beta-pregnanes from 17-oxo-steroids
US3492318A (en) * 1968-01-22 1970-01-27 Syntex Corp Cyclopropenyl androstanes
US3682983A (en) * 1969-11-12 1972-08-08 Klaus Prezewowsky Preparation of {66 {11 {11 -17 ethinyl steroids
FR2097045A1 (en) 1970-07-30 1972-03-03 Roussel Uclaf 17-ethynylgon-4-en-3-ones - with progestomimetic activity useful as contraceptives and for gynaecological disorders
US3681410A (en) * 1970-08-07 1972-08-01 Syntex Corp Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
US5155045A (en) 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
JP2578369B2 (ja) * 1989-05-09 1997-02-05 ポーラ化成工業株式会社 芳香組成物
GB8912043D0 (en) * 1989-05-25 1989-07-12 Beecham Group Plc Novel compounds
US5278141A (en) * 1992-03-24 1994-01-11 Erox Corporation Fragrance compositions containing human pheromones
US5272134A (en) * 1992-03-24 1993-12-21 Erox Corporation Fragrance compositions and other compositions which contain human pheromones

Also Published As

Publication number Publication date
ES2197949T3 (es) 2004-01-16
ATE240344T1 (de) 2003-05-15
MX9709693A (es) 1998-10-31
DE69628163D1 (de) 2003-06-18
NO975709D0 (no) 1997-12-05
HUP9900887A2 (hu) 1999-08-30
EP0830369A1 (de) 1998-03-25
EP0830369B1 (de) 2003-05-14
CA2223397A1 (en) 1996-12-19
AU724787B2 (en) 2000-09-28
CA2223397C (en) 2007-07-31
BR9609012A (pt) 1999-12-14
EP0830369A4 (de) 1999-06-09
CZ391597A3 (cs) 1998-06-17
JPH11507360A (ja) 1999-06-29
EA000965B1 (ru) 2000-08-28
KR19990022640A (ko) 1999-03-25
EA199800052A1 (ru) 1998-08-27
HUP9900887A3 (en) 1999-11-29
NZ312303A (en) 2000-01-28
US6242619B1 (en) 2001-06-05
WO1996040727A1 (en) 1996-12-19
DE69628163T2 (de) 2004-04-01
US5792757A (en) 1998-08-11
US5962443A (en) 1999-10-05
AU6380796A (en) 1996-12-30
CN1191542A (zh) 1998-08-26

Similar Documents

Publication Publication Date Title
CA2223397A1 (en) Novel nor-pregnanes for inducing hypothalamic effects
HUT77966A (hu) II.Típusú ösztrogénreceptor antagonista hatású flavanolignánokat tartalmazó antiproliferatív hatású gyógyszerkészítmények és azok előállítása
DK0794794T3 (da) Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler
NO974618L (no) Farmasöytiske preparater for intranasal administrasjon
NO990498L (no) 19-nor-cholansteroider som neurokjemiske initiatorer av forandring i human, hypotalamisk funksjon
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
FI956029A0 (fi) Androstaanisteroidit ihmisen hypotalaamisen toiminnan muuttamisen neurokemiallisina initiaattoreina sekä tähän liittyvät farmaseuttiset koostumukset ja menetelmät
NO955084L (no) Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
NO990305L (no) Steroider som neurokjemiske stimulatorer av VNO for Õ lindre symptomer av PMS og angst
NO971417L (no) Nye estrener for indusering av hypotalmiske effekter
MX9700881A (es) Pregnanos y colanos como indicadores neuroquimicos del cambio en la funcion hipotalamica.
JPS5849314A (ja) 抗副腎皮質機能低下症剤
MXPA94000705A (es) Esteroides de estreno como iniciadores neuroquimicos del cambio en la funcion hipotalamica humana ycomposiciones farmaceuticas y metodos relacionados.
DK0483320T3 (da) Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf
Sabol et al. The NMDA receptor antagonist MK-801 does not protect against serotonin depletions caused by high doses ofdl-fenfluramine
BR9816142A (pt) Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application